Evidence map›Paper›PMID 38902241›Full record

ArticleSignal transduction and targeted therapy2024

Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection.

Wenjing Zai, Min Yang, Kuan Jiang, Juan Guan, Huijing Wang, Kongying Hu, Chao Huang, Jieliang Chen, Wei Fu, Changyou Zhan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenjing Zai *Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Min Yang *Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Kuan JiangDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Juan GuanPharmacy Department of Huashan Hospital, Fudan University, Shanghai, P. R. China.
Huijing WangInstitute of Pediatric Translational Medicine, Shanghai Institute for Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Kongying HuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Chao HuangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Jieliang ChenKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Wei FuInstitute of Pediatric Translational Medicine, Shanghai Institute for Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. fuweizhulu@163.com.ORCID 0000-0003-2321-1057
Changyou ZhanDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China. cyzhan@fudan.edu.cn.ORCID 0000-0002-5215-2829
Zhenghong YuanKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China. zhyuan@shmu.edu.cn.

Funding

China Postdoctoral Science Foundation 2022M710744National Natural Science Foundation of China (National Science Foundation of China) 82125035National Natural Science Foundation of China (National Science Foundation of China) 82302505National Natural Science Foundation of China (National Science Foundation of China) 91842309
6 · The paper itself

Abstract

This study aimed to develop a pan-genotypic and multifunctional small interfering RNA (siRNA) against hepatitis B virus (HBV) with an efficient delivery system for treating chronic hepatitis B (CHB), and explore combined RNA interference (RNAi) and immune modulatory modalities for better viral control. Twenty synthetic siRNAs targeting consensus motifs distributed across the whole HBV genome were designed and evaluated. The lipid nanoparticle (LNP) formulation was optimized by adopting HO-PEG

Indexed as

Hepatitis B virusInterleukin-2NanoparticlesRNA, Small InterferingAnimalsHepatitis BHepatitis B, ChronicHumansLiposomesMiceRNA InterferenceRNAi TherapeuticsRNA, MessengerInterleukin-2Lipid NanoparticlesLiposomesRNA, MessengerRNA, Small Interfering

Identifiers

PMID38902241
PMCPMC11189933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.